Загрузка...
Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions
Prognosis of diffuse large B-cell lymphoma (DLBCL) has considerably improved during the last decade, mainly due to the addition of rituximab to chemotherapy. However, a significant proportion of patients still experience primary refractory disease or short-term relapses, conferring poor survival. Th...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3621721/ https://ncbi.nlm.nih.gov/pubmed/23579927 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S42574 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|